Black Rock Inc. Aldeyra Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,310,787 shares of ALDX stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,310,787

Previous 3,430,774 3.5%

Holding current value

$12.8 Million

Previous $12 Million 10.1%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.77 - $4.22 $332,363 - $506,345	-119,987 Reduced 3.5%	3,310,787 $10.8 Million
Q4 2023 Feb 13, 2024	BUY	$1.47 - $6.06 $87,673 - $361,430	59,642 Added 1.77%	3,430,774 $12 Million
Q3 2023 Nov 13, 2023	BUY	$6.11 - $8.16 $859,786 - $1.15 Million	140,718 Added 4.36%	3,371,132 $22.5 Million
Q2 2023 Aug 11, 2023	BUY	$7.11 - $11.89 $16 Million - $26.7 Million	2,245,432 Added 227.97%	3,230,414 $27.1 Million
Q1 2023 May 12, 2023	BUY	$5.77 - $9.93 $72,390 - $124,581	12,546 Added 1.29%	984,982 $9.78 Million

Q4 2022 Feb 13, 2023	BUY	$5.08 - $7.09 $11,938 - $16,661	2,350 Added 0.24%	972,436 $6.77 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $18,471 - $37,624	-4,861 Reduced 0.5%	970,086 $5.18 Million
Q2 2022 Aug 12, 2022	SELL	$2.43 - $4.85 $5.46 Million - $10.9 Million	-2,245,564 Reduced 69.73%	974,947 $3.89 Million
Q1 2022 May 12, 2022	SELL	$3.25 - $5.17 $26,975 - $42,911	-8,300 Reduced 0.26%	3,220,511 $14.3 Million
Q4 2021 Feb 10, 2022	SELL	$3.5 - $9.63 $122,958 - $338,311	-35,131 Reduced 1.08%	3,228,811 $12.9 Million
Q3 2021 Nov 09, 2021	SELL	$7.94 - $11.31 $94,025 - $133,933	-11,842 Reduced 0.36%	3,263,942 $28.7 Million
Q2 2021 Aug 11, 2021	BUY	$10.44 - $14.85 $34.2 Million - $48.6 Million	3,275,784 New	3,275,784 $37.1 Million

Others Institutions Holding ALDX

# of Institutions

106

Shares Held

35.4M

Call Options Held

104K

Put Options Held

88.1K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $225M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account